List of Excipients in Branded Drug EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

Generic Drugs Containing EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

Company	Ingredient	NDC	Excipient
Laurus Labs Limited	efavirenz, lamivudine and tenofovir disoproxil fumarate	42385-928	CELLULOSE, MICROCRYSTALLINE
Laurus Labs Limited	efavirenz, lamivudine and tenofovir disoproxil fumarate	42385-928	CROSCARMELLOSE SODIUM
Laurus Labs Limited	efavirenz, lamivudine and tenofovir disoproxil fumarate	42385-928	HYDROXYPROPYL CELLULOSE
Laurus Labs Limited	efavirenz, lamivudine and tenofovir disoproxil fumarate	42385-928	LACTOSE

What are the Most Frequently-Used Excipients in EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
1	FERRIC OXIDE YELLOW
2	HYDROXYPROPYL CELLULOSE

Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: September 24, 2026

The efavirenz/lamivudine/tenofovir disoproxil fumarate fixed-dose combination is a technically feasible, low-cost antiretroviral product aimed primarily at public-sector procurement and markets where efavirenz-based first-line therapy remains relevant. Its main formulation challenge is integrating poorly water-soluble efavirenz with more soluble lamivudine and tenofovir disoproxil fumarate while maintaining chemical stability, rapid dissolution, tablet robustness and low manufacturing cost.

The commercial opportunity is strongest in generic, tender-driven markets rather than in the United States or Western Europe. The active ingredients are small molecules with largely expired foundational patent barriers. Regulatory and commercial success will depend more on bioequivalence, manufacturing reliability, country-specific registration, WHO prequalification and procurement access than on composition-of-matter patent exclusivity.

What is the efavirenz, lamivudine and tenofovir disoproxil fumarate combination?

The proposed product is an oral, once-daily antiretroviral fixed-dose combination containing:

Active ingredient	Typical strength	Pharmacological class	Key formulation issue
Efavirenz	600 mg	Non-nucleoside reverse transcriptase inhibitor	Very low aqueous solubility; high dose; dissolution risk
Lamivudine	300 mg	Nucleoside reverse transcriptase inhibitor	Water soluble; generally straightforward to formulate
Tenofovir disoproxil fumarate	300 mg	Nucleotide reverse transcriptase inhibitor prodrug	Hydrolytic and moisture sensitivity; fumarate salt handling
Total active load	1,200 mg	Combination antiretroviral therapy	Large tablet, compression and swallowing constraints

This combination should not be confused with Atripla, which contains efavirenz, emtricitabine and tenofovir disoproxil fumarate. Atripla does not contain lamivudine. The distinction matters for regulatory precedent, patent analysis and bioequivalence strategy.

Efavirenz/lamivudine/tenofovir disoproxil fumarate products have been developed and supplied in certain international generic and public-health settings, but the exact regulatory status depends on the jurisdiction, manufacturer, strength and product presentation.

What excipient strategy is best for this fixed-dose combination?

A formulation should be designed around efavirenz dissolution and tenofovir disoproxil fumarate stability. Lamivudine is unlikely to be the rate-limiting component.

Recommended excipient architecture

A practical immediate-release tablet may use:

Formulation function	Candidate excipients	Development rationale
Diluent and compressibility	Microcrystalline cellulose, mannitol, lactose monohydrate or anhydrous lactose	Supports tablet hardness and dose uniformity
Efavirenz wetting and dissolution	Sodium lauryl sulfate, poloxamer or another qualified surfactant	Improves wetting of hydrophobic efavirenz
Disintegrant	Croscarmellose sodium, crospovidone or sodium starch glycolate	Supports rapid tablet breakup
Binder	Povidone or low-substituted hydroxypropyl cellulose	Improves granule and tablet strength
Flow aid	Colloidal silicon dioxide	Controls flow and reduces segregation
Lubricant	Magnesium stearate or sodium stearyl fumarate	Reduces ejection force
Moisture-control component	Low-moisture excipient grades and protective packaging	Reduces TDF degradation risk
Film coating	Hypromellose-based coating with titanium dioxide and colorant where permitted	Improves handling, identification and swallowability

The final composition must be selected through comparative dissolution, stability and bioequivalence testing. A direct-compression process offers lower cost and fewer unit operations, but the high active load and different powder properties may produce segregation, poor flow or inconsistent tablet weight. Wet granulation can improve content uniformity and compressibility, but water exposure must be controlled because tenofovir disoproxil fumarate is vulnerable to hydrolytic degradation.

Should the product use wet granulation or direct compression?

Direct compression is attractive when the selected grades of microcrystalline cellulose, mannitol and disintegrant provide adequate flow and compactability. It minimizes heat and water exposure and reduces manufacturing cost.

Wet granulation is more suitable when efavirenz distribution, tablet strength or dissolution is inadequate under direct compression. An aqueous process creates a greater risk of TDF degradation. If wet granulation is used, the process should limit liquid addition, drying time and residual moisture. Non-aqueous granulation may reduce hydrolytic exposure but introduces solvent controls, worker-safety requirements and residual-solvent testing.

A dry-granulation or roller-compaction process may offer a useful middle position. It improves powder flow and density without exposing the blend to water, although excessive compaction can slow disintegration and dissolution.

How should efavirenz dissolution be managed?

Efavirenz is the principal biopharmaceutical risk. Its low aqueous solubility can create dissolution-limited absorption and batch-to-batch variability.

The formulation program should evaluate:

1. Particle-size distribution and milling conditions.
2. Efavirenz polymorphic form and crystallinity.
3. Surfactant level and wetting performance.
4. Granule porosity and tablet compression force.
5. Dissolution across physiologically relevant pH conditions.
6. Similarity to the reference product or comparator selected for the registration pathway.
7. Food-effect behavior, because efavirenz exposure can change with high-fat meals.

A surfactant can improve efavirenz wetting, but excessive surfactant may reduce tablet strength, alter gastrointestinal tolerability or produce an unfavorable dissolution profile. Solid dispersion, spray drying or nanomilling could improve dissolution but would increase process complexity and cost. These technologies are most commercially justified where conventional formulation cannot meet bioequivalence requirements.

For a public-sector product, a conventional, scalable formulation is generally preferable to an advanced delivery system unless the latter materially improves bioequivalence or reduces tablet size.

What stability controls are required for tenofovir disoproxil fumarate?

Tenofovir disoproxil fumarate is the principal chemical-stability concern. Moisture, heat and prolonged exposure to unfavorable storage conditions can promote degradation.

A commercial control strategy should include:

• Low-moisture excipient grades.
• Controlled relative humidity during blending and compression.
• Short exposure times during granulation.
• Moisture-barrier film coating where compatible with dissolution.
• Alu-Alu blister packaging or high-barrier HDPE bottles.
• Desiccant use for bottle presentations where justified.
• Stability testing under long-term and accelerated ICH conditions.
• Monitoring of tenofovir-related degradation products.
• Container-closure integrity testing.
• In-process moisture controls for granules and finished tablets.

Alu-Alu blister packs may provide stronger moisture protection than standard PVC-based blisters, but they carry higher packaging cost. HDPE bottles may be more efficient for high-volume tenders and institutional supply, particularly when combined with induction seals and desiccants.

What tablet-size and patient-use issues affect commercial design?

The combined active load is approximately 1.2 grams before excipients and coating. A single tablet may therefore be large and difficult for some patients to swallow. Tablet size affects adherence, procurement acceptance and the ability to use standard high-speed compression equipment.

Commercial options include:

Product configuration	Advantages	Limitations
One large immediate-release tablet	Simplifies dosing and packaging	Large tablet; compression and dissolution challenges
Bilayer tablet	Separates incompatible powder streams or optimizes release	More complex equipment and process validation
Two-tablet co-pack	Easier formulation development	Loses the adherence and logistics advantage of a single FDC
Smaller high-density tablet	Reduces dimensions	May increase compression force and slow disintegration
Film-coated tablet	Improves handling and taste masking	Adds weight, process time and moisture exposure

A bilayer design is technically possible but may not be economically attractive for a low-margin product. It is most relevant where segregation, incompatibility or dissolution differences cannot be controlled in a single-layer tablet.

What patents protect efavirenz, lamivudine and tenofovir disoproxil fumarate products?

The foundational composition-of-matter patent barriers for efavirenz, lamivudine and tenofovir disoproxil fumarate have generally expired or ceased to block ordinary generic development in major markets. Current risk is more likely to arise from formulation, manufacturing, polymorph, process or method-of-use claims than from the active ingredients themselves.

Patent categories relevant to the proposed product

Patent category	Relevance to the FDC	Commercial risk
Composition-of-matter patents	Protect the active ingredient	Generally low for legacy molecules
Salt or crystal-form patents	May affect TDF or efavirenz solid-state forms	Moderate where claims remain enforceable
Fixed-dose-combination patents	Could cover ratios, dosage forms or specific excipients	Jurisdiction-specific
Formulation patents	May cover dissolution enhancement, coatings or granulation	Moderate
Manufacturing patents	May cover preparation of TDF or efavirenz intermediates	Relevant to API sourcing
Method-of-use patents	May cover treatment populations or dosing schedules	Usually less relevant to a conventional generic label
Regulatory exclusivity	Can delay approval independently of patents	Low for legacy small molecules in mature markets

The original U.S. patent for lamivudine dates to the early development era of the product, while efavirenz and tenofovir disoproxil fumarate also had early composition and formulation patents. Those historical barriers do not create a current broad exclusionary position for the active ingredients. A product-specific freedom-to-operate review remains necessary for any target country because patent term adjustments, supplementary protection certificates, national phase claims and later formulation patents differ by jurisdiction.

What is the FDA and Orange Book status?

A U.S. FDA-approved reference product containing efavirenz, lamivudine and tenofovir disoproxil fumarate as the exact three-drug combination is not established by the principal FDA labeling records for Sustiva, Epivir and Viread. Sustiva contains efavirenz, Epivir contains lamivudine, and Viread contains tenofovir disoproxil fumarate. Atripla contains efavirenz, emtricitabine and tenofovir disoproxil fumarate, not lamivudine.

As a result, the exact FDC should not be treated as having the same U.S. regulatory pathway as a generic version of Atripla. Key implications are:

• An ANDA pathway requires an appropriate reference listed drug and a legally supportable sameness strategy.
• A new combination may require an NDA or another pathway if no suitable reference product exists.
• FDA Orange Book listings for the individual products do not automatically cover the proposed three-drug combination.
• Patent certifications and Paragraph IV litigation depend on the reference product and patents identified in the relevant regulatory pathway.
• Regulatory approval in a WHO-prequalification or national pathway does not establish U.S. approval.

For non-U.S. markets, the product may be registered as a generic FDC where the local agency accepts the comparator, clinical rationale and bioequivalence package.

When does this product lose exclusivity?

For commercial purposes, the relevant active-ingredient exclusivity has already lapsed in most major jurisdictions. The product is therefore exposed to generic competition from the outset unless a later formulation or combination patent remains enforceable.

The practical exclusivity timeline is:

Period	Commercial position
Original launch period	Protected by active-ingredient and early formulation patents
Post-expiry period	Generic entry becomes legally feasible
Current market	Competition is driven by registration, quality, price and procurement access
New product launch	Any remaining protection must arise from product-specific formulation, process or combination claims

There is no biosimilar risk because this is a chemically synthesized small-molecule product. The relevant competitors are generic manufacturers, not biosimilar developers.

What Paragraph IV challenges and litigation risks exist?

A Paragraph IV challenge is relevant only where a U.S. generic applicant relies on an FDA reference product with Orange Book-listed patents. The absence of an exact U.S. reference product weakens the direct applicability of a conventional Paragraph IV strategy to this three-drug combination.

Potential litigation risks include:

• Alleged infringement of formulation patents.
• Disputes over efavirenz solid forms or particle-size limitations.
• Process claims covering tenofovir disoproxil fumarate manufacture.
• Patent claims covering a specific fixed-dose ratio.
• Regulatory disputes over the appropriate reference product.
• Trade-secret or know-how disputes involving granulation and stability controls.

No active U.S. patent litigation can be assigned to the exact FDC without a product-specific docket and jurisdictional review. The most material risk is likely to arise from country-level registration and procurement disputes rather than from blockbuster-style litigation over the active ingredients.

What commercial opportunities exist for the combination?

The strongest opportunities are in countries and procurement channels where:

• Efavirenz remains included in treatment guidelines.
• Tenofovir disoproxil fumarate and lamivudine remain accepted nucleoside backbones.
• Public tenders reward low unit cost.
• WHO prequalification or stringent national registration improves procurement access.
• A single-tablet regimen has adherence or logistics value.
• Heat and humidity stability is important.
• Existing treatment programs use efavirenz-based regimens.

The principal disadvantages are clinical and market-related. Many treatment guidelines have shifted toward dolutegravir-based regimens because of efficacy, resistance and tolerability considerations. Efavirenz can cause central nervous system adverse effects and has a lower strategic position in several modern first-line protocols. That reduces demand in high-income markets and in countries that have completed transition to integrase inhibitor-based therapy.

A manufacturer can still create value through:

• Low-cost WHO-prequalified supply.
• High-barrier packaging for tropical climates.
• Reliable batch release and low recall risk.
• Regional manufacturing or local-content advantages.
• Government tender participation.
• Co-packaging with other antiretroviral products.
• Flexible bottle and blister presentations.
• Contract manufacturing for originator-independent public-health programs.

How strong is the patent estate compared with newer HIV products?

The patent estate is weaker than that of newer branded HIV products. Legacy molecules such as efavirenz, lamivudine and tenofovir disoproxil fumarate have broad generic competition and limited practical exclusivity. Newer regimens containing dolutegravir, bictegravir or tenofovir alafenamide may have stronger remaining patent positions and higher commercial value, although their market access depends on country-specific licensing and procurement agreements.

Product type	Patent strength	Generic competition	Commercial outlook
Efavirenz/lamivudine/TDF FDC	Low to moderate, depending on formulation claims	High	Low-cost and tender markets
Efavirenz/emtricitabine/TDF	Mature generic market	High	Established but declining in many guidelines
Dolutegravir-based FDC	Stronger for some products and jurisdictions	Moderate to increasing	Higher clinical demand
Bictegravir-based FDC	Generally stronger proprietary position	Lower	Branded and selected generic opportunity
Tenofovir alafenamide combinations	Stronger formulation and product claims	Lower	Higher-value, patent-sensitive market

Key Takeaways

• Efavirenz is the primary dissolution challenge.
• Tenofovir disoproxil fumarate is the primary moisture and chemical-stability concern.
• Lamivudine is comparatively easy to formulate.
• Direct compression, dry granulation or controlled wet granulation are the main manufacturing options.
• Low-moisture excipients and high-barrier packaging are central to product stability.
• The exact combination is distinct from Atripla because Atripla contains emtricitabine, not lamivudine.
• The foundational active-ingredient patents are generally no longer the main barrier to entry.
• The exact three-drug FDC does not have the same U.S. Orange Book and ANDA position as an Atripla generic.
• No biosimilar issue exists; competition will come from small-molecule generic manufacturers.
• The best commercial targets are public-sector and tender markets where efavirenz-based therapy remains accepted.
• Dolutegravir-based products present the main competitive threat.

FAQs

Is efavirenz/lamivudine/tenofovir disoproxil fumarate the same as Atripla?

No. Atripla contains efavirenz, emtricitabine and tenofovir disoproxil fumarate. The proposed product contains lamivudine instead of emtricitabine.

Which excipient is most important for efavirenz dissolution?

A suitable wetting or surfactant system, combined with controlled particle size and tablet porosity, is usually more important than increasing the overall disintegrant level.

Is tenofovir disoproxil fumarate stable in conventional tablet formulations?

Yes, but the formulation and packaging must control moisture, heat and exposure during processing. High-barrier blisters or protected bottles may be required for demanding climatic zones.

Can the combination be approved through the FDA ANDA pathway?

The pathway depends on the availability of an appropriate U.S. reference listed drug and the legal basis for demonstrating sameness. The exact three-drug combination is not interchangeable with Atripla.

Is this combination commercially attractive against dolutegravir-based regimens?

It remains attractive where price, existing procurement systems and efavirenz-based guidelines support demand. Its commercial position is weaker in markets that have shifted decisively to dolutegravir-based first-line treatment.

References

1. European Medicines Agency. (2017). Atripla: EPAR product information. European Union.

2. U.S. Food and Drug Administration. (2019). Sustiva (efavirenz) prescribing information. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2019). Epivir (lamivudine) prescribing information. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2019). Viread (tenofovir disoproxil fumarate) prescribing information. U.S. Department of Health and Human Services.

5. World Health Organization. (2021). WHO guidelines for the use of antiretroviral drugs for treating and preventing HIV infection. WHO.

6. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. ICH.

7. International Council for Harmonisation. (2005). ICH Q9: Quality risk management. ICH.

8. International Council for Harmonisation. (2008). ICH Q10: Pharmaceutical quality system. ICH.

9. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.